![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Yupelri (revefenacin) is a novel small molecule, M3 receptor inhibitor. It is under phase 4 clinical studies in patients with severe to very severe chronic obstructive pulmonary disease (COPD).
Lead Product(s): Revefenacin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Yupelri
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2024
Details:
YUPELRI® (revefenacin) inhalation solution is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease.
Lead Product(s): Revefenacin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Yupelri
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
Enrollment of first patient in the Phase 4 PIFR-2 for YUPELRI® (revefenacin) is on the basis of continued investment in controlled clinical studies, that design to personalized treatment plans in order to make better-informed decisions for their COPD patients.
Lead Product(s): Revefenacin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Yupelri
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022